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Fibroblasts from a female patient carrying a heterozygous variation in GTP cyclohydrolase 1 (GCH1; OMIM:
600225; HGNC: 4193; c.235_240del/p.(L79_S80del)), the rate-limiting enzyme of tetrahydrobiopterin (BH4)
synthesis, were reprogrammed to iPSCs using the Cytotune®-iPS 2.0 Sendai Reprogramming Kit (Invitrogen) de-
livering the four reprogramming factorsOct3/4, Sox2, c-Myc and Klf4. Pluripotency of HDMC0061i-GCH1was ver-
iﬁed using immunohistochemistry and RT-PCR analysis. Cells differentiated spontaneously into the 3 germ layers
in vitro and presented a normal karyotype. HDMC0061i-GCH1 represents the ﬁrst model system to elucidate the
pathomechanism underlying this rare metabolic disease and a useful tool for drug testing.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Resource details
Fibroblasts from a female patient carrying a heterozygous variation
in GTP cyclohydrolase 1 (GCH1; OMIM: 600225; c.235_240del/
p.(L79_S80del); López-Laso et al., 2012) were reprogrammed using
the Cytotune®-iPS 2.0 Sendai Reprogramming Kit (Invitrogen) deliver-
ing the four human reprogramming factors Oct3/4, Sox2, c-Myc and
Klf4. Fluorescence R-banding was performed and provided a normal
diploid 46, XX karyotype (Fig. 1A). RT-PCR with Sendai virus-speciﬁc
primers (Table 1) was used to show absence of Sendai virus vector
(SeV; Fig. 1B). Absence of mycoplasma contamination in the parental ﬁ-
broblasts, during reprogramming and in the iPSC line itself was veriﬁed
by using a PCRMycoplasma Test Kit (AppliChem) (Fig. 1C). Presence of
the heterozygous variant was veriﬁed by PCR and subsequent Sanger
Sequencing (Fig. 1D). Pluripotency marker gene expression was ana-
lyzed by RT-PCR with gene-speciﬁc primers (Fig. 1E; Table 1) as well
as via immunoﬂuorescence staining for the pluripotency markers
Oct3/4, Sox2, Nanog, Lin28 and SSEA-4 (Fig. 1F). Embryoid body (EB)
formation followed by immunoﬂuorescence staining showing the pres-
ence of endodermal (AFP), mesodermal (SMA) and ectodermal (βIII-tu-
bulin) markers (Fig. 1G) and RT-PCR ampliﬁcation of AFP (endoderm),
TBX20 (mesoderm) and Nestin (ectoderm; Fig. 1H; Haase et al., 2009)
was used to show the differentiation potential of the iPSCs.
2. Materials and methods
2.1. iPSC reprogramming
Fibroblastswere cultured inDMEM(Invitrogen) supplementedwith
10% FBS (Invitrogen), 1% Penicillin/Streptomycin (Invitrogen), 0.1 mM
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Fig. 1.HDMC0061i-GCH1 iPSCs (p5) display a normal diploid karyotype (46, XX; A). Sendai virus was not detectable in untransduced ﬁbroblasts of the patient (Fib) or in iPSCs (iPSC, p7)
but in ﬁbroblasts seven days after transduction (d7; B). Nomycoplasma contamination was present in the ﬁbroblasts (Fib 6), during reprogramming (Tra6) or in the iPSCs itself (iPS) (C).
Presence of the heterozygous 6 bp deletion was veriﬁed by Sanger Sequencing showing presence of both the wildtype allele (marked as wildtype allele) and the deletion (marked as
c.235_240del allele) in the same DNA preparation of HDMC0061i-GCH1 (D). HDMC0061i-GCH1 iPSCs express several pluripotency marker genes as shown by RT-PCR (E) as well as by
immunoﬂuorescence staining (F). HDMC0061i-GCH1 iPSCs can be differentiated into all three germ layers as shown by immunoﬂuorescence staining (G) and RT-PCR (H).
Abbreviations: +: cDNA synthesis with reverse transcriptase;−: cDNA synthesis without reverse transcriptase; Tra6: Patient-speciﬁc ﬁbroblasts during reprogramming; Fib1, Fib4,
Fib5, Fib6: ﬁbroblasts isolated from different patients whereby Fib6 were used to generate HDMC0061i-GCH; iPS: HDMC0061i-GCH iPSCs; pos. co: positive control to show
functionality of mycoplasma detection in the PCR; d0: undifferentiated iPSCs; d15: differentiated iPSCs on day 15 of differentiation; d7: patient-speciﬁc ﬁbroblasts on d7 after
transduction with Sendai virus. Scale bars represent 100 μm.
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non-essential amino acids (Invitrogen) and 50 μM β-mercaptoethanol
(Invitrogen) and reprogrammed in passage 7 applying the Cytotune®-
iPS 2.0 Sendai Reprogramming Kit (Invitrogen) following the
manufacturer's instructions. Brieﬂy, cells were seeded at a density of
1 × 105 cells/well the day before transduction into two wells of a
Matrigel (BD Biosciences)-coated 6 well plate (Greiner). On the day of
transduction, one well was counted and necessary volumes for trans-
duction of each virus were calculated. Cells were transduced with an
MOI of 5 for KOS virus and hc-Myc virus, respectively, and an MOI of 3
for hKlf4 virus in a total volume of 1 ml growth medium. The following
day, medium was changed and cells were cultivated for 6 additional
days with a daily medium change. On day 7, transduced ﬁbroblasts
were trypsinized, counted, and seeded on 1 × 106 Mitomycin-treated
murine embryonic ﬁbroblasts (MEF;Merck-Millipore) per 100 cm gela-
tine-coated (0,1% gelatine (Sigma) inMilliQwater) petri dish (Sarstedt)
at a density of 2 × 105 transduced cells/plate, 1 × 105 transduced cells/
plate and 1 × 104 transduced cells/plate, respectively. Remaining cells
were washed with D-PBS (Invitrogen), spun down, frozen and used as
positive control for SeV-speciﬁc RT-PCR. The following day, medium
was changed to ESC medium (KnockOut DMEM, 20% Serum Replace-
ment, 0.1 mM non-essential amino acids, 50 μM β-mercaptoethanol,
1% penicillin/streptomycin (all from Invitrogen) and 4 ng/ml bFGF
(Peprotech)) and cells were cultivated for 21–27 more days with daily
medium change. Between days 21 and 27 post transduction colonies
with iPS-like morphology were manually picked, transferred to
Matrigel-coated (BD Biosciences) 12well plates (Greiner) containing
Essential 8™ Flex Medium (Invitrogen) and further expanded in a hu-
midiﬁed atmosphere containing 5% CO2 at 37 °C.
2.2. RT-PCR analysis
RNA was extracted with Trizol® (Invitrogen) according to the
manufacturer's instructions. 1 μg RNA was digested with DNaseI
(Invitrogen) to remove DNA contaminations and cDNAwas synthesized
from 0.5 μg DNaseI-digested RNA using SuperScript® III Reverse Tran-
scriptase and Oligo (dT)20 primer (both from Invitrogen) according to
the manufacturer's instructions. Expression of endogenous
pluripotency markers (Oct3/4, Sox2, Nanog, Lin28) or germ layer
markers (Nestin, AFP, TBX20) was monitored using Crimson Taq Poly-
merase (New England Biolabs) and standard PCR conditions (95 °C
30 s (1×); 95 °C 30 s, 55–62 °C 1 min, 68 °C 1 min (35×); 68 °C 5 min
(1×), 12 °C (hold); for details see Table 1). To show absence of Sendai
virus, GoTaq® Green Mastermix (Promega) was used for PCR (94 °C
2 min (1×); 94 °C 30 s, 55 °C 30 s, 72 °C 30 s (35×); 72 °C 5 min
(1×), 12 °C (hold)). PCR products were analyzed using agarose
gelelectrophoresis.
2.3. In vitro differentiation via embryoid body formation
iPSCs were harvested with ReLeSR™ (Stem Cell Technologies), sin-
gled and counted. 9 × 105cells/well were transferred to an AggreWell
800™ plate (Stem Cell Technologies) which contained ESC medium
supplemented with 10 μMROCK inhibitor (Y-27632; SIGMA) but with-
out bFGF to form uniform embryoid bodies (EBs) overnight. The next
day, EBs were transferred to an Ultra-low attachment plate (Greiner)
and cultivated for 6 additional days in ESC medium without bFGF. On
day 8, EBs were trypsinized and seeded onto gelatine coated plates
(containing cover slips for immunoﬂuorescence staining or nothing
for RNA isolation and RT-PCR). Cells were then cultured in differentia-
tion medium (ESC medium without bFGF/MEF medium 50:50 (v/v))
for 7 more days. On day 15, cells were ﬁxed with 4% paraformaldehyde
(PFA; Sigma) in PBS for immunoﬂuorescence staining or lysed using
Trizol® for RNA isolation and RT-PCR.
2.4. Immunoﬂuorescence staining
Presence of the pluripotency marker genes Oct3/4, Sox2, Nanog,
Lin28, and SSEA-4 or germ layer markers (AFP, ßIII tubulin, SMA) was
analyzed via immunoﬂuorescence staining. For detection of
pluripotency marker genes, iPSCs were seeded onto Matrigel-coated
(BD Biosciences) cover slips and cultivated in Essential 8™ Flexmedium
(Invitrogen) for 3–5 days before ﬁxation. iPSCs or differentiated cells
after EB formationwere ﬁxed in 4% PFA/PBS (15min, room temperature
(RT)) and permeabilized with 1% Triton X-100/PBS for 10 min at RT.
Blocking was performed with 5% BSA/0.1% Triton X-100/PBS for one
hour at RT. Then, cells were incubated in 5% BSA/PBSwith primary anti-
bodies (Table 2) for one hour at RT, followed by an incubation step with
the secondary antibodies (Table 2) in 5% BSA/PBS for 30min at RT. Cells
were mounted in Fluoromount-G with DAPI (eBioscience) to counter-
stain the nuclei and analyzed using a ﬂuorescence microscope (Leica)
and Leica Imaging Software.
2.5. Karyotyping
For Karyotyping, cells were trypsinized and metaphases were pre-
pared according to standard procedures. Fluorescence R-banding
using chromomycin A3 and methyl green was performed as described
Table 1
Primers used in the study.
Gene
symbol
Sequence
(fwd and rvs; 5′–3′)
Product
size (bp)
Annealing
temperature
(°C)
β-actin CATGGAGAAAATCTGGCACCAC 409 56
GCACAGCTTCTCCTTAATGTCAC
Oct3/4 GAACCAGTATCGAGAACCG 383 56
TCAGTTTGAATGCATGGGAG
Sox2 CACATGTCCCAGCACTACCAG 77 56
CACATGTGTGAGAGGGGCAG
Nanog AAACAGAAGACCAGAACTGTG 191 56
CAGTTGTTTTTCTGCCACCTCT
Lin28 CCATATGGTAGCCTCATGTC 126 56
CAATTCTGTGCCTCCGGG
Nestin CAGCGTTGGAACAGAGGTTGG 388 62
TGGCACAGGTGTCTCAAGGGTAG
AFP ACTCCAGTAAACCCTGGTGTTG 255 55
GAAATCTGCAATGACAGCCTCA
TBX20 AGGTACCGCTACGCCTAC 470 50
GTCAGTGAGCCTGGAGGA
SeV
(Sendai)
GGATCACTAGGTGATATCGAGC 181 55
ACCAGACAAGAGTTTAAGAGATATGTATC
Klf4
(Sendai)
TTCCTGCATGCCAGAGGAGCCC 410 55
AATGTATCGAAGGTGCTCAA
c-Myc
(Sendai)
TAACTGACTAGCAGGCTTGTCG 532 55
TCCACATACAGTCCTGGATGATGATG
GCH1 CAGCGAGGAGGATAACG 179 55
CGTTTAGGACATCTGAGATG
Table 2
Antibodies used for immunoﬂuorescence staining.
Application Antibody Dilution Company Cat. #
Pluripotency Mouse anti-Oct4 1:100 SantaCruz sc-5279
Mouse anti-Sox2 1:100 Merck
Millipore
MAB4343
Mouse anti-Nanog 1:100 Thermo
Fisher
MA1–017
Mouse anti-SSEA4 1:100 SantaCruz sc-21704
Rabbit anti-Lin28 1:100 SantaCruz sc-67266
Mouse anti-AFP 1:100 Abcam ab3980
Differentiation Rabbit anti-SMA 1:100 Abcam ab5694
Mouse anti-ßIII-Tubulin 1:100 Abcam ab78078
Secondary
antibodies
Alexa Fluor goat anti mouse
488
1:500 Thermo
Fisher
A-10667
Goat anti-Rabbit IgG (H + L),
TRITC conjugate
1:500 Thermo
Fisher
A16101
40 S. Jung-Klawitter et al. / Stem Cell Research 20 (2017) 38–41
in detail earlier (Schlegelberger et al., 1999). At least 20 metaphase
spreads were analyzed and evaluation was carried out at a minimum
level of 300 bands. Chromosomeswere classiﬁed according to the Inter-
national System for Human Cytogenetic Nomenclature (ISCN 2013;
Shaffer et al., 2013).
2.5. DNA isolation and sanger sequencing
To conﬁrm the presence of the heterozygous variation in the GCH1
gene, speciﬁc primers (Table 1) were designed for the ampliﬁcation of
the genomic region of interest. DNA was extracted from the iPSCs
usingDNAzol® (MRC Inc.) according to themanufacturer's instructions.
100 ng DNA was used for PCR with Crimson Taq Polymerase (New En-
gland Biolabs) using standard PCR conditions (95 °C 30 s (1×); 95 °C
30 s, 55 °C 30 s, 68 °C 30 s (35×); 68 °C 5min (1×), 12 °C (hold); for de-
tails see Table 1). PCR products were cloned into pGEM®-T Easy
(Promega) and 10 clones where sequenced by GATC Biotech (Köln,
Germany).
2.6. Detection of mycoplasma contamination
To show that the parental ﬁbroblasts and the derived iPSCs are free
of mycoplasma contamination the PCR Mycoplasma Test Kit
(AppliChem) was used according to the manufacturer's instructions.
In brief, 1.0 ml of cell culture supernatant was transferred into a
2.0 ml centrifuge tube. Cellular debris was pelleted by centrifugation
at 250 ×g for 3 min. The supernatant was transferred to a new 1.5 ml
tube, and centrifuged for 10 min at 13.000 rpm at room temperature.
The supernatant was discarded, the pellet was re-suspended in 50 μl
Buffer Solution, and heated for 3 min at 95 °C. Ampliﬁcation of the
16srRNA of a potential Mycoplasma contamination was performed
with the Reaction Mix provided by the manufacturer in a volume of
25 μl using the following PCR conditions: 94 °C 30 s (1×); 94 °C 30 s,
60 °C 2 min, 72 °C 1 min (35×); 94 °C 30 s, 60 °C 2 min, 72 °C 5 min
(1×), 12° (hold) followed by agarose gel electrophoresis.
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